CNSide at the Forefront of CNS Metastases Innovation in 2025
On July 10, 2025, Plus Therapeutics announced that its subsidiary, CNSide Diagnostics, LLC, will feature two compelling presentations at the 2025 SNO/ASCO CNS Metastases Conference, taking place August 14–16, 2025, in Baltimore, Maryland (GlobeNewswire).
Michael Rosol, Ph.D., Plus Therapeutics’ Chief Development Officer, stated:
“The CNSide data highlights its ability to quantify tumor cells and deliver actionable insights. The diagnostic assay is an exciting advancement for enhancing CNS metastases management and driving therapies like REYOBIQ™ in our ReSPECT-LM dose optimization trial.” (GlobeNewswire)
Both sessions will be presented by Dr. Priya Kumthekar, M.D., and will delve into the clinical utility of the CNSide CSF Assay Platform:
| Presentation Title | Topic Focus | Date & Time | Location |
|---|---|---|---|
| CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker Assessment Helps in Clinical Management of Breast Cancer and Non-Small Cell Lung Cancer Patients Having Leptomeningeal Disease (BIOM-04), FORESEE Study (NCT05414123) | Application of CNSide to manage leptomeningeal disease across breast and lung cancers | Thursday, August 14, 2025, 7:15 – 9:00 p.m. ET | Grand Ballroom VI |
| The Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease (LMD): Longitudinal Detection in CSF-TCs Reveals Implications for Differential Treatment of the LMD Tumor (BIOM-03) | Insights into longitudinal tumor behavior and treatment strategies | Friday, August 15, 2025, 3:25 – 4:50 p.m. ET | Grand Ballroom I–V |
Each presentation underscores how CNSide enables better quantification and characterization of tumor cells in CSF, key to advancing personalized care for patients with CNS metastases (GlobeNewswire).
Strategic Significance
- Clinical Relevance: These presentations reinforce CNSide’s role in elevating the standard of care for leptomeningeal metastases, particularly for high-risk patients with breast or lung cancer.
- Therapeutic Synergy: Demonstrating CNSide’s compatibility with initiatives like the ReSPECT-LM dose optimization trial supports its dual impact as both a diagnostic and treatment-enabling tool (GlobeNewswire, Nasdaq).
- Visibility in Oncology: Presenting at the combined SNO/ASCO conference amplifies CNSide’s reach and affirms its potential among peers and clinicians (GlobeNewswire, Nasdaq).
#CNSideDiagnostics #SNOSCO2025 #CNSMetastases #NeuroOncology #LeptomeningealMetastases #ReSPECTLM #CNSCancer #Biomarkers #DiagnosticsInnovation
0 Comments